浙江新光药业股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发的 深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上〔2022〕 14 号）的规定，将本公司募集资金 2023 年上半年存放与使用情况专项说明如下。 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2016〕1179 号文核准，本公司由主承销商太平 洋证券股份有限公司采用向社会公开发行方式，向社会公众公开发行人民币普通股（A 股） 股票 2,000 万股，发行价为每股人民币 12.20 元，共计募集资金 24,400.00 万元，坐扣承销 和保荐费用 1,700.00 万元后的募集资金为 22,700.00 万元，已由主承销商太平洋证券股份 有限公司于 2016 年 6 月 16 日汇入本公司募集资金监管账户。另减除上网发行费、招股说明 书印刷费、申报会计师费、律师费、评估费等与发 ...

证券代码：300519 独立董事发表的独立意见 浙江新光药业股份有限公司独立董事 关于第四届董事会第十一次会议相关事项的独立意见 浙江新光药业股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日召开 第四届董事会第十一次会议，根据相关法律、法规、规范性文件及公司章程的规 定， 我们作为公司独立董事，基于独立、客观、公正的立场，对会议审议的相 关事项发表独立意见如下： 一、关于公司 2023 年半年度控股股东及其他关联方占用公司资金、公司对 外担保情况、关联交易情况的独立意见 独立董事：____________、 _____________、 _____________ 二、关于《2023 年半年度募集资金存放与使用情况的专项报告》的独立意 见 经对公司 2023 年半年度募集资金存放与使用情况的核查，全体独立董事认 为：本专项报告符合《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》、《深圳证券交易所创业板股票上市规则》、《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》以及公司《募集资 金管理制度》等有关规定，内容真实、准确、完整，不存在虚假记载 ...

证券代码：300519 监事会审核意见 浙江新光药业股份有限公司监事会 关于第四届监事会第十一次会议审议事项的审核意见 根据《公司法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律法 规和浙江新光药业股份有限公司(以下简称"公司")《公司章程》、《监事会议 事规则》等公司制度的有关规定,公司监事会就第四届监事会第十一次会议审议 事项发表如下审核意见： 一、《关于公司 2023 年半年度报告全文及摘要的议案》的审核意见 经审核，监事会认为董事会编制和审核《公司 2023 年半年度报告》及 《2023 年半年度报告摘要》的程序符合法律、法规和中国证监会的有关规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 二、《关于 2023 年半年度募集资金存放与使用情况的专项报告的议案》的 审核意见 公司根据相关法律法规、规范性文件的规定签署募集资金专户存储监管协 议，对募集资金采取专户存储管理。公司制作的《2023 年半年度募集资金存放与 使用的专项报告》，及时、真实、准确、完整地披露了公司 ...

证券代码：300519 证券简称：新光药业 公告编号：2023-033 浙江新光药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席孙筑平召集，会议通知于 2023 年 8 月 16 日 以专人送达、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2023 年 8 月 23 日在公司三楼会议室召开，采取现场投 票的方式进行表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席孙筑平先生主持，公司董事会秘书、财务总 监和证券事务代表列席了本次监事会。 会议审议并通过了如下议案： 1、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审核《公司 2023 年半年度报告》及《2023 年半年度报告摘要》的程序符合法律、法规和中国证监会的有关规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 ...

证券代码：300519 证券简称：新光药业 公告编号：2023-028 浙江新光药业股份有限公司 关于持股 5%以上股东股份减持计划期限届满及 未来减持计划预披露的公告 持股 5%以上的股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2023 年 1 月 18 日就持股 5%以上股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）拟减持公司股 份的意向进行了预披露，和丰投资计划在自《关于持股 5%以上股东股份减持计划期 限届满及未来减持计划预披露的公告》（公告编号：2023-001）公告之日起 15 个交 易日后的 6 个月内，拟通过集中竞价交易方式减持公司股份合计不超过公司总股本 比例 2.00%。 公司于 2023 年 5 月 17 日披露了《关于持股 5%以上股东股份减持计划时间过半 的进展公告》（公告编号：2023-022）。上述具体内容详见公司刊登于中国证监会 指定的创业板信息披露媒体上的 ...

证券代码：300519 证券简称：新光药业 浙江新光药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------|----------------------------| | | ■特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □新闻发布会 | □业绩说明会□路演活动 | | 类别 | □现场参观 | | | | □其它 | （请文字说明其它活动内容） | 大成基金 徐雄晖、王敏杰 参与单位名称及 太平洋证券研究院 王均丽 人员姓名 时间 2023 年 6 月 21 日，14:00--15:30 地点 线上电话会议 上市公司接待人 公司副总经理、董秘 蒋源洋 员姓名 公司证券事务代表 裘大可 本次投资者关系活动以腾讯会议线上调研的方式进行，接待人 员与投资者进行了沟通交流，主要内容如下： 1、公司的业务整体介绍和近期经营情况解读。 答：公司主要从事中成药、化学药、保健食品的研发、生 投资者关系活动 产和销售。公司所生产药品治疗范围以心脑血管疾病、外伤科 疾病为主，涵盖了呼吸系统、消 ...

证券代码：300519 证券简称：新光药业 公告编号：2023-020 浙江新光药业股份有限公司 关于参加浙江辖区上市公司 2023 年投资者 网上集体接待日活动暨召开 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江新光药业股份有限公司（以下简称 "公司"）将参加由浙江证监局、浙江省上市公司协会与深圳市全景网络有限公 司联合举办的"2023 年浙江辖区上市公司投资者集体接待日活动"暨公司 2022 年度业绩说明会，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023 年 5 月 12 日（周五） 15:00-17:00。届时 公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告！ 浙江新光药业 ...

Financial Performance - The company's operating revenue for 2022 was CNY 351,488,810.60, representing a 9.54% increase compared to CNY 320,876,074.74 in 2021[19]. - The net profit attributable to shareholders for 2022 was CNY 108,821,010.06, a decrease of 4.78% from CNY 114,280,359.13 in the previous year[19]. - The net cash flow from operating activities decreased by 11.19% to CNY 126,429,397.43 in 2022, down from CNY 142,355,309.64 in 2021[19]. - The total assets at the end of 2022 were CNY 957,759,191.66, reflecting a 2.72% increase from CNY 932,403,805.04 at the end of 2021[19]. - The basic earnings per share for 2022 were CNY 0.68, down 4.23% from CNY 0.71 in 2021[19]. - The weighted average return on equity for 2022 was 12.88%, a decrease of 0.92% from 13.80% in 2021[19]. - The gross profit margin for the company was 51.85%, with a notable increase in operating costs by 19.07% to CNY 169.23 million[57]. - The company achieved total revenue of CNY 351.49 million, a year-on-year increase of 9.54%[45]. - The main products, Huangqi Shengmai Drink and Xiyangshen Oral Liquid, contributed 77.03% and 13.29% to total revenue, respectively[46]. - The company reported a decrease in cash flow from operating activities by 11.19%, amounting to CNY 12.96 million[45]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 5.00 per 10 shares, totaling CNY 80,000,000 based on 160,000,000 shares[4]. - The cash dividend distribution policy requires a minimum of 20% of the distributable profit to be allocated as cash dividends during the growth phase with significant capital expenditure[151]. - The company emphasizes a stable profit distribution policy, prioritizing cash dividends when conditions are met, and plans to distribute profits at least once a year[146]. - The cash dividend amount is based on the company's distributable profit of RMB 427,086,565.84 for the year[151]. - The company has no plans for stock dividends or capital reserve transfers for the reporting period[151]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is experiencing growth due to factors such as an aging population and increased health awareness[29]. - The company anticipates continued growth in the pharmaceutical market driven by ongoing healthcare reforms and increased government investment[29]. - The company aims for a revenue growth target of 0-10% for 2023 compared to the previous year[100]. - The company plans to enhance its marketing network, focusing on both domestic market cultivation and expansion into new markets, with an emphasis on quality and brand strategy[97]. - The company is currently in the process of converting prescription drugs to OTC products, which is expected to enhance market competitiveness[65]. Research and Development - Research and development expenses totaled CNY 15.55 million, representing 4.42% of total revenue[50]. - The company has completed multiple R&D projects, including the industrialization of Shengmai Drink and the development of new product standards[51]. - The company has allocated 1.5 billion for research and development in the next fiscal year, representing a 13% increase from the previous budget[196]. - The company is accelerating the construction of its "Modern Chinese Medicine R&D Center" and enhancing collaboration with research institutions to expedite new product development and technology application[98]. - The company has established partnerships with several research institutions for product innovation, holding 10 core independent intellectual property rights, including 6 invention patents[41]. Risk Management - The company is actively monitoring potential risks including industry policy changes and market expansion challenges[3]. - Future challenges include pressures from healthcare cost control and price reductions due to centralized procurement policies[36]. - The company faces risks from policy changes in the healthcare sector, which may impact sales regions and pricing, necessitating proactive adjustments in marketing strategies[102]. - The company will closely monitor raw material price fluctuations, as significant increases could adversely affect profitability[104]. Governance and Compliance - The company emphasizes investor relations management, utilizing multiple channels for communication and actively responding to investor inquiries[112]. - The company has a clear governance structure with independent committees, including nomination, audit, strategy, and compensation committees, providing professional advice to the board[110]. - The company has implemented effective internal audit measures to oversee financial reporting and risk management, ensuring asset security[112]. - The company has a structured decision-making process for profit distribution, involving independent directors and communication with minority shareholders[149]. - The company has established a comprehensive internal control system to mitigate operational risks and enhance management quality[153]. Social Responsibility and Environmental Compliance - The company donated 1 million yuan to the Shenzhou Charity Association to support education, healthcare, and assistance programs during the reporting period[164]. - The company maintained compliance with environmental standards, with actual emissions of COD and ammonia nitrogen within the approved limits[161]. - The company has implemented a complete environmental self-monitoring plan and has passed the ISO14001 environmental management system certification[161]. - The company emphasizes social responsibility, aiming to improve human life quality and promote a harmonious relationship with society[164]. Employee Management - The total number of employees at the end of the reporting period is 308, with 182 in production, 47 in sales, 43 in technical roles, 11 in finance, and 25 in administration[142]. - The educational background of employees shows that 77 hold a bachelor's degree or higher, 82 have a college diploma, and 149 have education below college level[143]. - The company has implemented a differentiated compensation policy based on department, position, and job nature to enhance employee motivation and efficiency[144]. - The training program includes various categories such as corporate culture, technical skills, project management, and management skills, with a focus on continuous education and evaluation of training effectiveness[145].

Financial Performance - The company's operating revenue for 2022 was CNY 351,488,810.60, representing a 9.54% increase compared to CNY 320,876,074.74 in 2021[18]. - The net profit attributable to shareholders for 2022 was CNY 108,821,010.06, a decrease of 4.78% from CNY 114,280,359.13 in the previous year[18]. - The net cash flow from operating activities was CNY 126,429,397.43, down 11.19% from CNY 142,355,309.64 in 2021[18]. - The basic earnings per share for 2022 was CNY 0.68, a decline of 4.23% from CNY 0.71 in 2021[18]. - Total assets at the end of 2022 amounted to CNY 957,759,191.66, reflecting a 2.72% increase from CNY 932,403,805.04 at the end of 2021[18]. - The net assets attributable to shareholders increased by 1.50% to CNY 858,894,551.23 at the end of 2022, compared to CNY 846,217,071.35 in 2021[18]. - The company reported a non-recurring profit of CNY 3,860,332.04 in 2022, a decrease of 27.1% compared to CNY 5,297,980.58 in 2021[24]. - The company received government subsidies amounting to CNY 1,631,993.38 in 2022, an increase of 7.5% from CNY 1,517,346.62 in 2021[24]. Operational Highlights - The company plans to distribute a cash dividend of CNY 5.00 per 10 shares, totaling CNY 80,000,000.00 based on 160,000,000 shares[4]. - The company reported a weighted average return on equity of 12.88% for 2022, down from 13.80% in 2021[18]. - The company achieved total revenue of CNY 351.49 million, a year-on-year increase of 9.54%[44]. - The main products, Huangqi Shengmai Drink and Xiyangshen Oral Liquid, saw revenue growth of 9.18% and 29.28% respectively, while Shenjindan Capsule revenue decreased by 4.54%[45][55]. - The company's gross profit margin was 51.85%, with operating costs rising by 19.07% to CNY 169.23 million[56]. - The company invested CNY 135.97 million in fundraising projects, including the construction of a GMP production line for Huangqi Shengmai Drink[48]. - R&D expenses totaled CNY 15.55 million, representing 4.42% of total revenue, focusing on product innovation and process optimization[49]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is experiencing growth due to factors such as an aging population and increased healthcare awareness[28]. - The company anticipates that the demand for pharmaceutical products will continue to grow due to ongoing healthcare reforms and an increasing elderly population[30]. - The company is focusing on the industrialization of its products, including the recovery of production for key medications, which is expected to bring new economic growth points[64]. - The company plans to strengthen its marketing network, focusing on both provincial and out-of-province market expansion, to cultivate new growth points for leading products[97]. - The company aims to promote the modernization and globalization of traditional Chinese medicine, aligning with national strategies to enhance healthcare services[94]. - The company is actively expanding its marketing network and seeking to develop markets outside of Zhejiang province, where over 70% of its revenue is generated[103]. Research and Development - The company has established a high-tech research and development center and collaborates with several universities for product innovation, holding 10 core independent intellectual property rights[40]. - The company has developed sugar-free versions of its products to cater to the growing number of diabetes patients, indicating a proactive approach to market demands[36]. - The company is focusing on strategic acquisitions to bolster its market presence and product offerings[199]. - The company plans to continue its research and development efforts in new products and technologies to enhance its market position[199]. Risk Management - The company anticipates facing risks related to industry policy changes, healthcare policy changes, and fluctuations in raw material prices[3]. - Future challenges include pressures from medical insurance cost control and centralized procurement, which may impact drug pricing and sales[35]. - The company is monitoring the volatility of raw material prices, which could adversely affect profitability if prices rise significantly[104]. - The company is addressing the risk of product structure concentration, as its main products account for a significant portion of revenue, and is working to expand its product market[103]. Corporate Governance - The company has established a complete and independent financial institution, with a robust accounting system and independent financial decision-making capabilities[117]. - The company maintains an independent operational structure, ensuring no overlap in business activities with its controlling shareholders[115]. - The performance evaluation and incentive mechanisms for senior management are transparent and aligned with the company's development status[114]. - The company has a clear governance structure, including independent boards and committees, adhering to legal and regulatory requirements[116]. Environmental and Social Responsibility - The company has maintained compliance with environmental standards, with actual emissions of COD at 1.26 tons and ammonia nitrogen at 0.011 tons, both within the permitted limits[162]. - The company donated 1 million yuan to the Shenzhou Charity Association to support education, healthcare, and poverty alleviation initiatives during the reporting period[165]. - The company has implemented a comprehensive environmental self-monitoring plan, ensuring timely recording of monitoring results and immediate corrective actions if standards are not met[163]. Future Outlook - In 2023, the company has set a preliminary operating target of 0% to 10% growth compared to the same period last year[100]. - The company plans to accelerate the construction of the "Modern Traditional Chinese Medicine R&D Center" in 2023, leveraging the advantages of technology, information, and talent in Hangzhou[99]. - The company anticipates that its earnings per share and return on equity will decline in the short term due to the significant increase in share capital and net assets following the IPO[172]. - The company is focused on increasing sales revenue and operating profit to offset the dilution of immediate returns[173].

Financial Performance - The company's operating revenue for Q1 2023 was ¥92,296,717.31, a decrease of 9.42% compared to ¥101,895,419.99 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥30,445,257.47, down 28.90% from ¥42,819,141.85 year-on-year[4] - The net profit for the reporting period decreased by 28.90% to ¥30,445,257.47 compared to ¥42,819,141.85 in the previous period, primarily due to a decline in operating income, rising raw material prices, and reduced bank interest income[3] - Earnings per share (EPS) for Q1 2023 was CNY 0.19, compared to CNY 0.27 in the previous year[22] Cash Flow - The net cash flow from operating activities decreased by 52.79% to ¥28,027,614.00 from ¥59,363,672.75 in the previous year[4] - The net cash increase from operating activities for Q1 2023 was CNY 1,901,807.18, compared to CNY 15,437,078.93 in Q1 2022, indicating a decrease of approximately 87.7%[24] - Cash flow from operating activities generated a net amount of CNY 28,027,614.00, significantly lower than CNY 59,363,672.75 in Q1 2022[23] - The company's cash and cash equivalents increased slightly to ¥623,931,587.44 from ¥622,029,780.26 at the beginning of the year[17] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥962,178,694.98, a decline of 1.73% from ¥979,092,999.45 at the end of the previous year[4] - Total liabilities decreased to CNY 72,704,969.26 from CNY 98,864,640.43 year-on-year[21] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 623,931,587.44, up from CNY 609,104,874.84 at the end of Q1 2022, reflecting an increase of about 2.7%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 17,562, with the top 10 shareholders holding a combined 59.75% of shares[1] - Wang Yuejun is the largest shareholder, holding 61,200,000 shares, representing 38.25% of total shares[1] Investment and Expenses - The company reported a significant reduction in accounts receivable, down 65.05% to ¥8,319,064.64 from ¥23,805,357.02[8] - Total operating costs increased to CNY 57,913,730.09, up 9.5% from CNY 52,906,632.17 year-on-year[20] - Research and development expenses for Q1 2023 were CNY 3,581,334.49, a decrease from CNY 3,966,483.95 in the same period last year[21] Other Financial Metrics - The weighted average return on equity decreased to 3.48% from 4.93% year-on-year[4] - Other comprehensive income after tax decreased by 35.17% to ¥133,917.02 from ¥206,552.12, mainly due to changes in the fair value of other equity instrument investments[3] - The net cash outflow from investment activities for Q1 2023 was CNY 26,125,806.82, an improvement compared to a net outflow of CNY 43,926,593.82 in Q1 2022, representing a reduction of approximately 40.5%[24] Audit and Reporting - The report for Q1 2023 was not audited, which may affect the reliability of the financial data presented[25]